Skip to main content
graph.swiss
Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

48.27 CHF+1.17 (+2.47%)
XSWX:BMYMarket Closed
ListedCHF98.6BHealthcareDrug Manufacturers - General32,500 employees

Company Profile

Legal NameBristol-Myers Squibb Company
CEODr. Christopher S. Boerner Ph.D.
HeadquartersRoute 206 & Province Line Road
Phone609 252 4621
Employees (FTE)32,500
SectorHealthcare
IndustryDrug Manufacturers - General

Business Description

Bristol-Myers Squibb Company is a global biopharmaceutical company headquartered in Princeton, New Jersey, and founded in 1933. It discovers, develops, licenses, manufactures, markets, distributes, and sells innovative medicines addressing serious diseases worldwide. The company offers a diverse portfolio including small molecule drugs, biologics produced from biological processes, and advanced chimeric antigen receptor (CAR-T) cell therapies. Key therapeutic areas encompass oncology with treatments like nivolumab (Opdivo) and ipilimumab (Yervoy), hematology featuring lenalidomide (Revlimid) and luspatercept (Reblozyl), immunology such as abatacept (Orencia), cardiovascular including apixaban (Eliquis), neuroscience, and other immunology and fibrosis-related conditions. Bristol-Myers Squibb Company plays a vital role in the healthcare sector by providing therapies for cancer, immune disorders, cardiovascular diseases, and beyond, serving patients through collaborations and a focus on unmet medical needs in these critical markets.

Profitability & Growth

Profitability

Profit Margin+15.01%
Operating Margin+33.04%
Return on Equity (TTM)+38.73%
Return on Assets (TTM)+10.69%

Recent Year-End

Revenue39.20B
Revenue / Share23.82
Gross Profit28.22B
EBITDA19.03B
Diluted EPS2.89
Earnings Growth YoY+9.00%
Revenue Growth YoY+2.60%

Balance Sheet Snapshot

Total Cash (MRQ)

8.48B

Total Debt (MRQ)

37.54B

Current Ratio (MRQ)

1.42

Book Value / Share

7.95

Stock Statistics

Shares Outstanding2.04B
Float Shares2.04B
Avg Volume (10d)50
Avg Volume (90d)17
% Held by Insiders+0.08%
% Held by Institutions+83.78%

Valuation

Market Cap98.57B
Enterprise Value108.78B
Trailing P/E14.72
PEG Ratio1.78
Price / Sales (TTM)1.79
Price / Book (MRQ)5.35
EV / Revenue2.77
EV / EBITDA7.09

Price Summary

52-Week Low42.54
52-Week High48.50
50-Day MA45.21
200-Day MA45.72
Beta0.23

Dividends

Forward Div Rate2.03
Forward Div Yield+4.21%
Trailing Div Rate0.51
5Y Avg Div Yield+321.00%
Payout Ratio+17.65%
Dividend Date2019-05-01
Ex-Dividend Date2026-07-02